
    
      This study is a multi-center, non-comparative, and phase IV clinical trial that evaluates the
      efficacy and safety of combined Once-Daily Tacrolimus (TacroBell SR Cap.) administration for
      24 weeks in patients with immunosuppressive therapies after renal transplantation.
    
  